Esaote Unveils I-Genius for Intraoperative MRI at AANS Congress

Esaote, a leader in medical imaging technology, has introduced its latest innovation, the I-Genius open MRI system, at the American Association of Neurological Surgeons (AANS) Annual Meeting in San Antonio, Texas. The I-Genius system is designed specifically to enhance intraoperative imaging during brain tumor surgeries, notably glioma resections.

The development of the I-Genius system is the result of a collaborative effort between Esaote's research and development teams and leading neurosurgeons. This innovative MRI technology seeks to provide real-time imaging capabilities during complex brain surgeries, facilitating multiple MRI checks without moving the patient. This feature is particularly crucial in glioma surgeries, where complete tumor removal is challenging and precise imaging can significantly impact surgical outcomes.

The open MRI design of the I-Genius allows it to be integrated seamlessly into the surgical environment. As the patient remains on the same table throughout the operation, surgeons can access crucial MRI data without interrupting the workflow. This approach reduces intraoperative challenges and supports real-time decision-making, ultimately aiming to enhance surgical precision and care standards.

Massimo Olmi, MRI Marketing Director at Esaote, highlighted the system's potential to revolutionize neurosurgical procedures: "I-Genius represents Esaote's first foray into intraoperative MRI, offering a solution tailored to neurosurgeons' needs. By delivering high-precision imaging and streamlining the surgical process, we aim to improve operating-room efficiency, cut costs, and significantly reduce procedure times."

Dr. Roberto Herrera, Chief of Neurosurgery at Clinica Adventista Belgrano in Buenos Aires, commented on the historical challenges of glioma surgery, noting that traditional practices relied heavily on indirect tools and surgical experience. "Intraoperative MRI systems like I-Genius provide real-time visualizations, fundamentally changing how surgeries are conducted by shifting from estimation to objective measurement," he explained. "This advancement is crucial for distinguishing tumors from healthy brain tissue and can potentially enhance the accuracy and completeness of tumor resections."

Currently, the I-Genius system is pending FDA approval and is not yet available for sale in the United States. However, its introduction at the AANS Congress has commenced the process of moving this cutting-edge technology closer to U.S. neurosurgical markets.